 Avalon GloboCare Corp. AVCO, a leading clinical-stage global developer of cell-based technologies and therapeutics, today announced it has secured a 20 million credit facility provided by the Companys Chairman, Daniel Lu. The unsecured credit facility bears interest at a rate of 5 and provides for maturity on drawn loans 36 months after funding. The credit facility will be used to accelerate the Companys ongoing research and development programs, clinical studies, as well as commercial strategies. 